Download MSD CINV App APK latest version Free for Android
Version | 1.0.3 |
Update | 54 years ago |
Size | 2.63 MB (2,756,562 bytes) |
Developer | moPharma Digital Solutions Pvt. Ltd. |
Category | Apps, Medical |
Package Name | com.moPharma.MSDeMETOGENICITY |
OS | 2.1 and up |
MSD CINV App APPLICATION description
Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared side effects of cancer treatment1-3.Inadequately controlled emesis significantly impairs quality of life1.
e-MANAgE is a tool in the form of an App to guide physician in evaluating the emetogenecity level of chemotherapy (single/ combination) administered to their patients and in turn better management of CINV
The concept of the e-MANAgE is to provide a reliable method of predicting the risk of emesis following cancer chemotherapy.
This App is developed by MSD Pharmaceuticals Pvt. Ltd., India.
Copyright © 2015 MSD Pharmaceuticals Pvt. Ltd.,
a subsidiary of Merck Sharp & Dohme Corp.,
Whitehouse Station, N.J., U.S.A. All rights reserved.
ONCO-1142625-0000 25/02/2015 24/02/2016
Reference:
1) Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens:
relevance to clinical practice. Oncologist. 1999;4(3):191-6.
2) Coates A, Abraham S, Kaye SB, et al. On the receiving end: patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983;19(2):203-8.
3) Griffin AM, Butow PN, Coates AS, et al. On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol. 1996;7(2):189-95.
e-MANAgE is a tool in the form of an App to guide physician in evaluating the emetogenecity level of chemotherapy (single/ combination) administered to their patients and in turn better management of CINV
The concept of the e-MANAgE is to provide a reliable method of predicting the risk of emesis following cancer chemotherapy.
This App is developed by MSD Pharmaceuticals Pvt. Ltd., India.
Copyright © 2015 MSD Pharmaceuticals Pvt. Ltd.,
a subsidiary of Merck Sharp & Dohme Corp.,
Whitehouse Station, N.J., U.S.A. All rights reserved.
ONCO-1142625-0000 25/02/2015 24/02/2016
Reference:
1) Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens:
relevance to clinical practice. Oncologist. 1999;4(3):191-6.
2) Coates A, Abraham S, Kaye SB, et al. On the receiving end: patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983;19(2):203-8.
3) Griffin AM, Butow PN, Coates AS, et al. On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol. 1996;7(2):189-95.